Rainbow Rare Earths Phalaborwa project shaping up to be one of the lowest cost producers globally. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Solid base here now at this level.
Next news from Markuu and away we go.
Hurry up Markku ;)
Cwebb, 360 as I type... Feeling very bullish today..
Would love some news to drop and the SP rise to 10 quid :)
Indeed Itsall.
Never felt as confident in Farn despite the extended timesacles with Bexmarilimab and the Clever 1 find and now with T starting in the US with government funding and without steroid interference.
When you look at some of the rises in other shares can easily see that here with the right announcement.
I expect we will see the next Clevegen update in around 7 weeks, the way things are progressing could that be the trigger for a partner to come on board? That could be a massive push towards £10+
Traumakine news is likely to be confirmation we have dosed the first patient in HIBISCUS that could land any day now but I don't expect that will have a massive effect on the SP...we might have to wait a couple of months for the first read outs before boom time.
With regards to the DoD trials that will be less easy to predict and an update could drop anytime, hard to even guess what that could mean for the SP as we know very little about the trials .
Any sniff of a non dilutive Stateside listing especially combined with the commencement of our HIBISCUS trial over there and we are likely to see some very positive movement. All in all its looking like a great time to be holding!
We could also get interim results from re-map at any time, which are out of our control.
Exciting times ahead!!
No panic here. Just the usual tree shake before news lands!
Absolutely Oil.
True finishing SP is 351.
A 1 trade at 330 brought it down.
From a selfish perspective i’m hoping news doesn’t land until Kistos relists. Then i’ll get some profit from there back into here.
I must add though it’s been a frustrating with lack of news to get us into the £10 region.
Our day will come. Fortune doesn’t just favour the brave, it favours the patience or this case patients!
Was checking an old share of mine today that I sold 2yrs ago for a modest profit.
If I sold them today I would have made £232k.
I won't be making the same mistake twice lol
Last paragraph from the April 10th announcement from Remap-cap.
https://www.remapcap.org/covid19publications
The link was removed. Maybe it comes through like this:
www.remapcap.org/covid19publications
Well here is the article from remap-cap site:
Equivalency of Tocilizumab and Sarilumab
April 10, 2021
The REMAP-CAP investigators are pleased to share additional results from the COVID-19 Immune Modulation Domain.
Previously, an adaptive analysis revealed that within the COVID-19 Immune Modulation Domain both tocilizumab and sarilumab had reached platform conclusions for efficacy when compared to the ‘no immune modulation’ intervention. As a result, the ‘no immune modulation’ intervention was closed, and the COVID-19 Immune Modulation Domain continued as a comparison between available active interventions (anakinra, interferon-ß1a, tocilizumab, and sarilumab). Since this time, more than 900 additional participants have been randomised to this domain.
The results of the most recent adaptive analysis, communicated to the REMAP-CAP International Trial Steering Committee by the DSMB, indicate that tocilizumab and sarilumab have now reached the pre-specified statistical trigger for equivalence.
These results provide a clear indication that tocilizumab and sarilumab are equally effective for the treatment of patients with severe COVID-19, and are also the most effective interventions included in this domain. The REMAP-CAP ITSC have therefore decided to pause recruitment to this domain. A full analysis of all interventions included in this domain, including anakinra and interferon-ß1a, will be completed and the results made available as soon as possible.
Yes I saw that the other day , wasn't really sure what to think , other than since the bulk of sites are in UK , where steroids are standard of care , the number of patients eligible for IFN Beta1 just didn't make up enough to be assessed yet .
I spoke to the lady at REMAP a month ago about this , as was told that although the UK etc mostly have steroids , the drug was still open to sites that were not using steroid as a first care drug , ie other countries I guess .
They have now paused the domain , and we should get some read out on what they have with our drug soon ( going on the speed at which this happens , I'd say Q3 )
It may prove inconclusive , due to low numbers . Adaptive trials by their nature swing towards the drugs that are doing well ( steroids for example ) . That finding ( back in Sept 2020 ) , pretty much put us to the back of the queue in REMAP - which we all knew . Hence Faron continuing to get Hibsicus funded , and run under their own protocols to let the drug really get proven up .
I like many are actually focused on Bexmarilimab for 2021 . That news will blow away any negative Traumakine sentiment , which to be honest has already been reflected in the SP . That info has been sitting on REMAP website since the weekend , and the SP over on the Nas has actually gone up .